Proficio Capital Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) ...

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

On Tuesday, 11 March 2025, Supernus Pharmaceuticals (NASDAQ: SUPN) presented at the Barclays 27th Annual Global Healthcare Conference, outlining its strategic direction and financial performance. The ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. 2. These restricted stock units were settled in common stock upon vesting, which ...

Supernus Pharmaceuticals CEO will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2025. Supernus Pharmaceuticals, Inc., a biopharmaceutical company specializing ...